A federal judge in Denver has hit pause on Colorado's first-in-the-nation price cap for Enbrel, putting a marquee drug-cost experiment on ice before it ever got off the ground.
On Wednesday, Chief U.S. District Judge Daniel D. Domenico temporarily blocked the state's Prescription Drug Affordability Board from enforcing its planned upper payment limit on Amgen's blockbuster arthritis drug. The policy was set to kick in starting in 2027. For now, that cap is sidelined while Amgen's lawsuit plays out, a setback for Gov. Jared Polis's push to rein in prescription costs and a fresh test of how far states can go in leaning on prices for patented medicines.
Judge Cites Patent Law And Harm To Amgen
In granting a preliminary injunction, Domenico concluded that Amgen was likely to suffer significant and irreparable harm if the price cap went forward and that federal patent law probably preempts the state's effort.
"As a matter of basic economic logic, Amgen is likely to be significantly harmed by a cap on the price of its product," the judge wrote, according to Reuters. That concern, paired with his view of federal patent protections, was enough for Domenico to freeze the rule while the broader legal fight continues.
How The State Set The Cap
Colorado's Prescription Drug Affordability Board settled on an upper payment limit of $600 per 50-milligram unit for Enbrel, which amounts to roughly $31,200 per year for a standard adult dose. That number came after months of rulemaking and hearings, with the rule scheduled to take effect on Jan. 1, 2027.
The board's adopted rule and meeting materials, including staff memos and the final rulemaking documents, are posted by the Colorado Division of Insurance, which oversees the PDAB, according to the Colorado Division of Insurance. The rule relied on Medicare's maximum fair price as a benchmark, tying Colorado's ceiling to a federal reference point.
Amgen's Lawsuit And Court Filings
Amgen responded by suing in federal court, arguing that the state-imposed cap would undercut its patent protections, violate due process, and inflict economic injury on the company. In its view, the state was effectively rewriting the balance Congress set between innovation incentives and price competition.
Court filings reviewed by the Georgetown Law Litigation Tracker show that Amgen sought a preliminary injunction and told the court it would have to decide by July 5 whether to withdraw Enbrel from sale in Colorado if it did not receive relief.
Patients, Advocates And The Board
Consumer advocates who had championed the PDAB process said the injunction lands hardest on patients struggling with high drug costs.
"This is a step backwards for Colorado and consumers," Adam Fox of the Colorado Consumer Health Initiative said in a statement, as reported by The Colorado Sun. Supporters had framed the Enbrel cap as a test case for tackling prices on other expensive drugs.
The PDAB was also examining potential upper payment limits for other biologics, including Stelara and Cosentyx, but those reviews are now effectively in legal limbo while the Enbrel case moves forward.
Why The Judge Looked To Federal Precedent
Domenico did not write on a blank slate. Federal courts have previously found that state price controls can clash with federal patent policy, and he leaned on those earlier rulings in his opinion.
The Federal Circuit's decision in Biotech Industry v. District of Columbia, which struck down a Washington, D.C. price rule, has become a key reference point for judges asked to decide if a state cap improperly "rebalances" the patent system designed by Congress, according to Justia. Domenico cited that precedent in assessing Colorado's Enbrel limit.
What Happens Next
The preliminary injunction will stay in place while the underlying lawsuit proceeds, which means the Enbrel cap cannot be enforced for now. The case could take months to resolve as both sides continue filing briefs and, potentially, appeal any final decision.
Amgen said it was "pleased" with the ruling and expressed confidence in its legal position, while state officials declined to comment on the ongoing litigation, according to The Colorado Sun. The outcome will be watched closely by other states and consumer groups as similar affordability boards weigh their own moves on high-cost drugs.
